Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Simon P L Travis

Showing results (1-10 of 85) with videos related to

Pageof 9
Sort By:
Current Opinion in Gastroenterology|July 16, 2008
Therapy of ulcerative colitis: state of the artOliver Brain, Simon P L Travis
European Journal of Gastroenterology & Hepatology|December 17, 2005
Weight loss at high altitude: pathophysiology and practical implicationsNoor Hamad, Simon P L Travis
Current Drug Targets|March 10, 2010
How to manage the infectious risk under anti-TNF in inflammatory bowel diseaseEmma L Culver, Simon P L Travis
Gut|July 31, 2012
Mucosal healing in inflammatory bowel diseases: a systematic reviewMarkus F Neurath, Simon P L Travis
Intestinal Research|May 11, 2018
Why is it so difficult to evaluate faecal microbiota transplantation as a treatment for ulcerative colitis?Natalie Grace Fairhurst, Simon P L Travis
European Journal of Gastroenterology & Hepatology|March 1, 2003
Thiopurine therapy: when to start and when to stopDermot P B McGovern, Simon P L Travis
Scandinavian Journal of Gastroenterology|December 20, 2014
Conventional drug therapy for inflammatory bowel diseaseRobert V Bryant, Oliver Brain, Simon P L Travis
Frontiers in Gastroenterology (Lausanne, Switzerland)|March 13, 2026
The continuing value of mesalazine as first-line therapy for patients with moderately active ulcerative colitisKristine Paridaens, Matthew J Freddi, Simon P L Travis
Current Medical Research and Opinion|August 18, 2021
Efficacy and safety of oral Pentasa (prolonged-release mesalazine) in mild-to-moderate ulcerative colitis: a systematic review and meta-analysisKristine Paridaens, John R Fullarton, Simon P L Travis
JGH Open : an Open Access Journal of Gastroenterology and Hepatology|July 27, 2023
Efficacy of oral prolonged-release mesalazine in moderately active ulcerative colitisKristine Paridaens, John R Fullarton, Simon P L Travis
Pageof 9

Showing results (1-10 of 85) with videos related to

Sort By:
Pageof 9
Current Opinion in Gastroenterology|July 16, 2008
Therapy of ulcerative colitis: state of the artOliver Brain, Simon P L Travis
European Journal of Gastroenterology & Hepatology|December 17, 2005
Weight loss at high altitude: pathophysiology and practical implicationsNoor Hamad, Simon P L Travis
Current Drug Targets|March 10, 2010
How to manage the infectious risk under anti-TNF in inflammatory bowel diseaseEmma L Culver, Simon P L Travis
Gut|July 31, 2012
Mucosal healing in inflammatory bowel diseases: a systematic reviewMarkus F Neurath, Simon P L Travis
Intestinal Research|May 11, 2018
Why is it so difficult to evaluate faecal microbiota transplantation as a treatment for ulcerative colitis?Natalie Grace Fairhurst, Simon P L Travis
European Journal of Gastroenterology & Hepatology|March 1, 2003
Thiopurine therapy: when to start and when to stopDermot P B McGovern, Simon P L Travis
Scandinavian Journal of Gastroenterology|December 20, 2014
Conventional drug therapy for inflammatory bowel diseaseRobert V Bryant, Oliver Brain, Simon P L Travis
Frontiers in Gastroenterology (Lausanne, Switzerland)|March 13, 2026
The continuing value of mesalazine as first-line therapy for patients with moderately active ulcerative colitisKristine Paridaens, Matthew J Freddi, Simon P L Travis
Current Medical Research and Opinion|August 18, 2021
Efficacy and safety of oral Pentasa (prolonged-release mesalazine) in mild-to-moderate ulcerative colitis: a systematic review and meta-analysisKristine Paridaens, John R Fullarton, Simon P L Travis
JGH Open : an Open Access Journal of Gastroenterology and Hepatology|July 27, 2023
Efficacy of oral prolonged-release mesalazine in moderately active ulcerative colitisKristine Paridaens, John R Fullarton, Simon P L Travis
Pageof 9